Recent Activity

Loading...

CRBU

Caribou Biosciences, Inc. · NASDAQ

Performance

-7.12%

1W

-15.46%

1M

-50.94%

3M

-28.33%

6M

-40.84%

YTD

-22.78%

1Y

Profile

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Investment Analysis Report: CRBU

Overview

CRBU is a biotechnology company operating in the Health Technology sector with a market capitalization of $611,059,177. In this investment analysis report, we will delve into the financial health, valuation, earnings and revenue growth, profitability, operating margin, operating cash flow analysis, and c...

See more ...

Technical Analysis of CRBU 2024-05-10

Overview:

In analyzing the technical indicators for CRBU over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and recommendations for potential future price action.

...
See more ...

Recent News & Updates